|
YALE COMPREHENSIVE CANCER CENTER
|
5P30CA016359-30
|
$1,889,710
|
$18,897
|
EDELSON, RICHARD
|
YALE UNIVERSITY
|
|
Whole Body Hyperthermia and Anti-Tumor Immune Response
|
5R01CA071599-10
|
$283,824
|
$56,765
|
REPASKY, ELIZABETH
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-25
|
$453,250
|
$4,533
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
|
5R01CA079218-09
|
$328,425
|
$16,421
|
Gill, Parkash
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
VCU Minority-Based CCOP
|
5U10CA052784-18
|
$577,110
|
$5,771
|
ROBERTS, JOHN
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Variation in NTP use by the HCV polymerase and response to therapy
|
3R21CA125321-02S1
|
$20,868
|
$20,868
|
TAVIS, JOHN
|
SAINT LOUIS UNIVERSITY
|
|
Variation in NTP use by the HCV polymerase and response to therapy
|
5R21CA125321-02
|
$147,000
|
$147,000
|
TAVIS, JOHN
|
SAINT LOUIS UNIVERSITY
|
|
UT M.D. Anderson Cancer Center SPORE in Melanoma
|
5P50CA093459-05
|
$2,158,606
|
$431,721
|
GRIMM, ELIZABETH
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
UT M.D. Anderson Cancer Center
|
5U10CA045809-20
|
$1,758,769
|
$35,175
|
FISCH, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
3P30CA014089-33S1
|
$74,165
|
$1,483
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
5P30CA014089-33
|
$6,658,653
|
$133,173
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035119-24
|
$1,880,470
|
$18,805
|
BEARDEN, JAMES
|
SPARTANBURG REGIONAL MEDICAL CENTER
|
|
UNMC Eppley Cancer Center Support Grant
|
3P30CA036727-24S1
|
$80,987
|
$810
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
UNMC Eppley Cancer Center Support Grant
|
5P30CA036727-24
|
$1,553,887
|
$15,539
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
University of Rochester Cancer Center CCOP Research Base
|
3U10CA037420-24S1
|
$46,973
|
$2,349
|
Morrow, Gary
|
UNIVERSITY OF ROCHESTER
|
|
University of Rochester Cancer Center CCOP Research Base
|
5U10CA037420-24
|
$1,338,526
|
$66,926
|
Morrow, Gary
|
UNIVERSITY OF ROCHESTER
|
|
University of Maryland Greenebaum Cancer Center Support Grant
|
1P30CA134274-01
|
$1,463,613
|
$73,181
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
University of Colorado Southwest Oncology Group
|
3U10CA042777-21S1
|
$420,576
|
$21,029
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
University of Colorado Southwest Oncology Group
|
5U10CA042777-21
|
$82,101
|
$4,105
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
Univ.of Calif., Irvine Cancer Center Support Grant
|
3P30CA062203-13S4
|
$2,630,152
|
$78,905
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
Univ.of Calif., Irvine Cancer Center Support Grant
|
3P30CA062203-13S5
|
$61,584
|
$1,848
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
U10 Ful Member Application Affiliated with SWOG
|
5U10CA105409-05
|
$71,573
|
$3,579
|
LIPPMAN, SCOTT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Tumor-mediated impairment of IL-12 gene expression
|
5K01CA101926-03
|
$153,873
|
$153,873
|
TORROELLA-KOURI, MARTA
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Tumor-induced immune suppression.
|
5R01CA115880-03
|
$253,359
|
$126,680
|
OSTRAND-ROSENBERG, SUZANNE
|
UNIVERSITY OF MARYLAND BALT CO CAMPUS
|
|
Tumor Induced Dysregulation of T Cell Immunity
|
5R01CA116255-03
|
$261,665
|
$13,083
|
FINKE, JAMES
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Treatment of Infections in Immunocompromised Children
|
Z01 SC 006830
|
$1,957,171
|
$195,717
|
Walsh, Thomas
|
CCR (NCI)
|
|
Training in Cancer Biology
|
5T32CA009547-23
|
$509,782
|
$25,489
|
SCHREIBER, ROBERT
|
WASHINGTON UNIVERSITY
|
|
Toll Receptor Ligand Therapy of Cutaneous T-Cell Lymphoma
|
1R01CA122569-01A2
|
$283,500
|
$141,750
|
ROOK, ALAIN
|
UNIVERSITY OF PENNSYLVANIA
|
|
TOLEDO COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035415-25
|
$721,858
|
$7,219
|
SCHAEFER, PAUL
|
TOLEDO COMMUNITY HOSPITAL ONCOLOGY PROG
|
|
Therapeutic Modulation of COX-2-induced Immunosuppression in Metastatic RCC
|
5R21CA123854-02
|
$293,550
|
$293,550
|
RINI, BRIAN
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
The Role of Toll-Like Receptors in Cancer Immunotherapy
|
3R01CA111807-04S1
|
$53,973
|
$10,795
|
YANG, YIPING
|
DUKE UNIVERSITY
|
|
The Role of Toll-Like Receptors in Cancer Immunotherapy
|
5R01CA111807-04
|
$288,390
|
$57,678
|
YANG, YIPING
|
DUKE UNIVERSITY
|
|
The role of Toll-like receptor 3 in overcoming cancer immunoediting
|
5K22CA122828-02
|
$162,047
|
$40,512
|
Bell, Jessica
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
The role of cellular miRNA in Epstein-Barr virus oncogenesis
|
1F32CA130469-01A2
|
$52,898
|
$13,225
|
Cameron, Jennifer
|
TULANE UNIVERSITY OF LOUISIANA
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-15S1
|
$91,948
|
$2,758
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-15S2
|
$49,383
|
$1,481
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-15S3
|
$83,152
|
$2,495
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
5P30CA060553-15
|
$5,084,061
|
$152,522
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-33S1
|
$89,606
|
$896
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
5P30CA016058-33
|
$3,753,703
|
$37,537
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Importance of T cell Survival in Tumor Immunity
|
5R01CA122701-02
|
$270,370
|
$67,593
|
WEINBERG, ANDREW
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
The Immunobiology of Marrow Allografts for Leukemia
|
5P01CA023766-30
|
$2,959,846
|
$147,992
|
O'REILLY, RICHARD
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
The Gulf Coast MBCCOP
|
7U10CA128536-02
|
$539,869
|
$5,399
|
BEEKER, THADDEUS
|
PROVIDENCE HOSPITAL (MOBILE, AL)
|
|
The functions of the US3 protein kinase of herpes simplex virus
|
2R01CA088860-06A1
|
$385,000
|
$115,500
|
ROIZMAN, BERNARD
|
UNIVERSITY OF CHICAGO
|
|
The function and regulation of histocompatibility antigen 60 in cancer
|
1K08CA128893-01A1
|
$127,170
|
$127,170
|
BUI, JACK
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
The connection of innate and adaptive anti-cancer immunity
|
Z01 BC 010970
|
$369,762
|
$295,810
|
Greiner, Jack
|
CCR (NCI)
|
|
The Brooklyn Minority-Based Community Clinical Oncology*
|
5U10CA114671-02
|
$554,189
|
$16,626
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
TCR Diagnostics in LGL Leukemia and Immune Cytopenias
|
5R01CA113972-04
|
$286,517
|
$28,652
|
Maciejewski, Jaroslaw
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Targeting myeloma via dendritic cells
|
7R01CA109465-04
|
$309,925
|
$77,481
|
DHODAPKAR, MADHAV
|
YALE UNIVERSITY
|
|
Targeted antigen receptor treatment of cancer
|
5P01CA033049-25
|
$2,161,758
|
$216,176
|
SCHEINBERG, DAVID
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
Total relevant funding to Interferon for this search: $35,442,662
|